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Abstract
Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer.
These heritable mutations are unequally represented among populations with different ethnic background due
to founder effects and thereby contribute to differences in breast cancer rates in different populations. The BRCA1
mutation c.5266dupC (also known as 5382insC or 5385insC) was detected in a sample of 193 breast cancer patients
in Ukraine by multiplex mutagenically separated PCR using published specific primers. Nine BRCA1 mutations 5382insC
were detected (4.7 %). The difference in age of diagnosis (35 years in 5382insC carriers versus 45 years in non-carriers)
we observed is consistent with other reports indicating that the 5382insC mutation is a factor of genetic predisposition
to breast cancer, which is consistent with reports from other countries.
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Findings
The BRCA1 gene is critical for a number of important
cellular processes, such as maintenance of genome integ-
rity, repair of DNA double-strand breaks, and cell cycle
control [1]. Mutations in BRCA1 and BRCA2 are associ-
ated with an increased risk of breast cancer, and is
reported to be as high as 80 % [2], and also associated with
ovarian, prostate, pancreatic and male breast cancer [3–5].
Breast cancer is the most frequent type of cancer in
Ukrainian women and is the primary cause of cancer-
related deaths. A total of 17,537 patients were diagnosed
with breast cancer in 2011 (including 130 men) corre-
sponding to a standardized incidence rate of 23.9 per
100,000 individuals [6], similar to that of other Eastern
European countries (22.07 in Moldova, 45.86 in Belarus,
50.04 in Romania, 50.54 in Hungary, 51.89 in Poland)
but far less than that of the United States (92.93) [7].
Knowledge of the presence of a BRCA1 mutation is
important for both prevention of cancer and personalized
treatment. Intensive screening of mutation carriers with
magnetic resonance imaging is now recommended in
developed countries [8–11]. Genetic testing at the time
of diagnosis facilitates choice of treatment and BRCA1
carriers with breast cancer may benefit from bilateral
mastectomy, from oophorectomy and from cisplatinum
treatments [12, 13]. Unfortunately, in Ukraine, genetic
screening is not currently offered at the time of breast
cancer diagnosis [14–18].
The frequency of BRCA1 mutations has been shown to
differ among ethnic backgrounds [13, 19–22], reaching as
high as 2.5 % in Ashkenazi Jews [19, 21, 22]. A small num-
ber of studies of Ukrainian women breast cancer patients
[14–18] have revealed the presence of a founder mutation
in BRCA1, 5382insC. This is the most common mutation
among Slavic patients with breast or ovarian cancer and
has been studied extensively in Poland, Russia, Belarus
and the Baltic countries. Here we present the results of a
screening for the frequency of the BRCA1 mutations
5382insC among 193 Ukrainian breast cancer patients.
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Patient samples
We screened 193 breast cancer patients diagnosed at
different ages. Data on each patient were collected from
their clinical records, accessed with the patients’ permis-
sion. We documented family history (FH) of disease in
135 patients out of 193 persons. Clinical material was
collected at the Shupik National Postgraduate Education
Medical Academy, the Kyiv Municipal Clinical Onco-
logical Center, the Ukrainian National Cancer Institute,
the Chernihiv Regional Oncology Center, and the
Zhytomyr Regional Oncology Center with informed con-
sent and approval from the local ethics committee (com-
mittee on Bioethics: order number №16 Educational and
Scientific Centre “Institute of Biology”, Taras Shevchenko
National University of Kyiv of February 25, 2014, 64
Volodymyrska St., 01601, Kyiv). DNA from blood samples
was extracted using the phenol-chloroform method and
by the DNA-SORB-B (AmpliSense, Russia). The BRCA1
mutation 5382insC was detected by multiplex mutageni-
cally separated PCR using published specific primers [23].
Three primers were used to detect the mutation: one
general, one specific to the mutation in question, and one
specific to wild the type allele as described in Chan et al.,
1999 [23]. PCR amplicons were analyzed by 8 % PAGE
and 2 % agarose.
We screened a total of 193 breast cancer patients diag-
nosed ages 18 through 80 for the 5382insC mutation. A
total of nine BRCA1 5382insC mutations were detected
(4.7 %) (Table 1). Most carriers of the 5382insC mutation
were younger that 40 years at the time of detection (ages
19, 27, 31, 34, 36, 38, 39), although two occurrences were
found in older patients (52 and 44 years). This represents
a frequency of occurrence of 7/79 (8.9 %) for individuals
under age 40 and 2/114 (1.8 %) for patients older than 40.
A mutation was found in 5 of 90 patients with a FH of
cancer (5.5 %) and in 1 of 45 patients with no FH (2.2 %).
13 patients with a FH of cancer had precisely breast
cancer in family (1 with mutation) and 77 patients with a
FH had other cancer types: prostate, stomach, lung cancer
and uterine fibroids (2 with mutation), also 14 patients
had both, breast and other cancer types in FH, such as
laryngeal, lung and prostate cancer (2 mutation carriers).
The frequency of the 5382insC mutation is similar in
patients with and without a FH of breast cancer (F = 0.01,
p > 0.05).
In this study, we report that 4.7 % of unselected breast
cancer patients from Ukraine carry a 5382insC mutation.
This estimate is similar to those of previous studies that
estimated the prevalence of the mutation between 2.5 %
and 7.1 % (F = 0.45, p > 0.05) [14–18]. Combining the
results of all studies, including ours, the pooled frequency
for Ukrainian patients is estimated at 5.81 ± 0.9 % (38
cases out of the total 654 women patients screened).
Ukrainians are eastern Slavics by genetic background
and are close relatives of Belarusians, Poles, and Russians.
The estimate of the 5382insC mutation in the BRCA1
gene for Ukraine (5.8 %) is higher than reported for
Belarusians (2.5 %) (F = 9.23, p < 0.05) [24], but lower
than that of Poles (10.4 %) (F = 12.21, p > 0.05) [25]
and is similar to an estimate from Saint Petersburg,
Russian (4.7 %) (F = 0.42, p > 0.05) [26].
The average age amounted 35 years in 5382insC carriers
versus 45 years in non-carriers which is consistent with
other reports indicating that the 5382insC mutation is a
factor of genetic predisposition to breast cancer, which is
also consistent with reports from other countries [27].
The 5382insC mutation of BRCA1 is a frequent germ-
line mutation in Ukrainian breast cancer patients. Inter-
estingly, and in contrast to other reports, our results
suggest no difference in 5382insC mutation frequencies
between breast cancer patients with and without a FH of
the disease. The presented data can confirm a noticeable
contribution of BRCA1 5382insC mutation in breast can-
cer development in Ukraine and as there is no difference
between the frequency of mutations in the groups with
and without a FH it may justify to screen for 5382insC
mutation all breast cancer patients totally, not primarily
that who have a FH.
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Table 1 Frequency of the 5382insC mutation in breast cancer
patients
Age >30 30–39 40–49 50–59 60–69 ≤70
n 24 54 48 34 27 6
Mutation 2 5 1 1 0 0
Frequency, % 8.3 9.2 2.0 2.9 0 0
Gorodetska et al. Hereditary Cancer in Clinical Practice  (2015) 13:19 Page 2 of 3
Received: 10 April 2015 Accepted: 7 October 2015
References
1. O’Donovan PJ, Livingston DM. BRCA1 and BRCA2: Breast/ovarian cancer
susceptibility gene products and participants in DNA double-strand break
repair. Carcinogenesis. 2010;31:961–7.
2. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer
due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12:245–59.
3. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al.
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and
peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA.
2006;296(2):185–92.
4. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among
male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.
2007;99(23):1811–4.
5. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation
carriers. Br J Cancer. 2007;96(1):11–5.
6. Cancer in Ukraine, 2013–2014 Ukrainian cancer registry statistics,
2014 Bulletin of National Cancer Registry of Ukraine. http://www.ncru.inf.ua/
7. Organisation for Economic Cooperation and Development. Health at a
glance: Europe 2010. OECD, 2010. http://ec.europa.eu/health/reports/docs/
health_glance_en.pdf
8. Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH,
et al. Relevance and efficacy of breast cancer screening in BRCA1 and
BRCA2 mutation carriers above 60 years: A national cohort study. 2014.
doi:10.1002/ijc.28941.
9. Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M,
et al. An analysis of polymorphisms within the Wnt signaling pathway in
relation to ovarian cancer risk in a Polish population. Mol Diagn Ther.
2014;18:85–91.
10. McCarthy AM, Armstrong K. The role of testing for BRCA1 and BRCA2
mutations in cancer prevention. JAMA Intern Med. 2014;174:1023–4.
11. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting
paradigms in personalized cancer care and prevention. Science.
2014;343:1466–70.
12. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction
strategies forBRCA1/2mutation carriers. J Clin Oncol. 2010;28:222–31.
13. Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB,
et al. Intentions for risk-reducing surgery among high-risk women
referred for BRCA1/BRCA2 genetic counseling. Psychooncology. 2014.
doi:10.1002/pon.3560.
14. Zakhartseva LM, Gorovenko NG, Podolskaya SV, Anikusko NF, Lobanova OE,
Pekur KA, et al. Breast cancer immunohistochemical features in young
women with BRCA1/2 mutations. Exp Oncol. 2009;31:174–8.
15. Kitsera NI, Shparyk IV, Bilynskyi BT, Tril OV, Mashalyga MS, Oleksyak OO, et al.
Analysis of mutations in the genes BCRA1/2 in patients withfamily/
hereditary breast cancer which live in the Lviv region (Ukraine). Onkologiia.
2012;11:44–9 (in Ukrainian).
16. Kruk TV, Peresunko OV, Volkov RA. A molecular genetics study of the
types of BRCA1 gene mutations in breast cancer patients and their
relatives in the Chernivtsi region of Ukraine. Novoutvorennia.
2012;12:310–4 (in Ukrainian).
17. Hossein R. Molecular genetic markers of breast cancer in patients of
different age groups. PhD thesis. 2012.
18. Rybchenko LA. Optimization of mutations determination in the BRCA1/2
genes for medical genetic counseling of women about breast cancer.
PhD thesis. 2014.
19. Karami F, Mehdipour P. A comprehensive focus on global spectrum of
BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013.
doi:10.1155/2013/928562.
20. Navarro de Souza A, Groleau D, Loiselle CG, Foulkes WD, Wong N. Cultural
aspects of healthy BRCA carriers from two ethnocultural groups. Qual Health
Res. 2014;24:665–81.
21. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al.
Germline BRCA mutation evaluation in a prospective triple-negative breast
cancer registry: implications for hereditary breast and/or ovarian cancer
syndrome testing. Breast Cancer Res Treat. 2014;145:707–14.
22. Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer. 2004;3:249–57.
23. Chan PC, Wong BY, Ozcelik H, Cole DE. Simple and rapid detection of
BRCA1 and BRCA2 mutations by Multiplex Mutagenically Separated PCR.
Clinical Chemistry. 1999;45:1285–7.
24. Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk
T. High frequency and allele-specific differences of BRCA1 founder
mutations in breast cancer and ovarian cancer patients from Belarus. Clin
Genet. 2010;78(4):364–72.
25. Gaj P, Kluska A, Nowakowska D. High frequency of BRCA1 founder
mutations in Polish women with nonfamilial breast cancer. Familial Cancer.
2012;11:623–8.
26. Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG,
Chekmariova EV, et al. High frequency of BRCA1 5382insC mutation in
Russian breast cancer patients. Eur J Cancer. 2006;42:1380–4.
27. Edlich RF, Winters KL, Lin KY. Breast cancer and ovarian cancer genetics.
J Long Term Eff Med Implants. 2005;15(5):533–45.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gorodetska et al. Hereditary Cancer in Clinical Practice  (2015) 13:19 Page 3 of 3
